智通财经APP讯,迪哲医药(688192.SH)公告,公司自主研发的产品舒沃哲®(ZEGFROVY®,通用名:舒沃替尼片)单药一线治疗表皮生长因子受体(EGFR)20号外显子插入突变(exon20ins)晚期非小细胞肺癌(NSCLC)的国际多中心III期临床研究“悟空28”(WU-KONG28)达到主要研究终点、取得阳性顶线结果,是全球首个且唯一在国际多中心随机对照III期临床研究中,针对EGFRexon20ins NSCLC一线治疗取得阳性结果的口服靶向药物。
智通财经APP讯,迪哲医药(688192.SH)公告,公司自主研发的产品舒沃哲®(ZEGFROVY®,通用名:舒沃替尼片)单药一线治疗表皮生长因子受体(EGFR)20号外显子插入突变(exon20ins)晚期非小细胞肺癌(NSCLC)的国际多中心III期临床研究“悟空28”(WU-KONG28)达到主要研究终点、取得阳性顶线结果,是全球首个且唯一在国际多中心随机对照III期临床研究中,针对EGFRexon20ins NSCLC一线治疗取得阳性结果的口服靶向药物。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.